Skip to content
🔴 Confirmed Attendees:
Arrakis Therapeutics • AstraZeneca • Bayer • CHDI • Chugai Pharmaceuticals • Dewpoint Therapeutics • Eli Lilly & Co. • EPICS Therapeutics • Fralin Biomedical Research Institute at VTC • Institut Pasteur • Nippon Shinyaku • Novartis • Pfizer • Prism Biolab • PTC Therapeutics • Remix Therapeutics • Renasis Bio • ReviR Therapeutics • RevoNA Bio • Rgenta Therapeutics • Ribometrix • Ribonaut Therapeutics • Sanofi • Schrodinger • Skyhawk Therapeutics • Syrna Therapeutics • UNC at Chapel Hill • University of Colorado Boulder • University of Toronto • University of Wisconsin-Madison • Veritas In Silico • Wayfinder Biosciences
November 10-12, 2026 | Boston, MA
Why Attend?
About The Summit
Attending Companies
Who Should Attend?
Large Pharma Leaders
Biotech Executives, Founders & CSOs
Biotech Drug Developers
Discovery & Translational Scientists
Academic Researchers
Testimonials
Events in the Series
Hanson Wade Products
What’s On?
What’s New for 2026?
Full Event Guide
2026 Speakers
Agenda
Pre-Conference Workshop Day
Conference Day One
Conference Day Two
Poster Session
Partnerships
Why Partner
2026 Sponsors
2026 Media Partners
Attendance
Pricing & Registration
Venue & Accommodation
Contact Us
Event Guide
Register
Why Attend?
About The Summit
Attending Companies
Who Should Attend?
Large Pharma Leaders
Biotech Executives, Founders & CSOs
Biotech Drug Developers
Discovery & Translational Scientists
Academic Researchers
Testimonials
Events in the Series
Hanson Wade Products
What’s On?
What’s New for 2026?
Full Event Guide
2026 Speakers
Agenda
Pre-Conference Workshop Day
Conference Day One
Conference Day Two
Poster Session
Partnerships
Why Partner
2026 Sponsors
2026 Media Partners
Attendance
Pricing & Registration
Venue & Accommodation
Contact Us
November 10-12, 2026 | Boston, MA
Event Guide
Register Interest
Positioning Long Non-Coding RNAs as Druggable Cancer Targets Through Small Molecule Modulation
Positioning Long Non-Coding RNAs as Druggable Cancer Targets Through Small Molecule Modulation
10:45 am - Thursday 12th November 2026
Exploring lncRNAs as actionable targets in prostate cancer
Targeting SChLAP1 with selective small molecule approaches
Sharing emerging toxicity and xenograft data
in vivo
Speakers:
Amanda Hargrove
Director & Professor - Medicinal Chemistry
University of Toronto
Scroll To Top